Aberrant markers expression in leukemia patients: a report from Western Iran

Leukemias comprise approximately 8% of the entire human cancers, and around 50% of these cases are classified as acute leukemia. The aim of this study was to evaluate the aberrant markers in Leukemias in the West of Iran. In an analytical-descriptive study, we analyzed the report of flowcytometry of peripheral blood samples from leukemia patients in Dr. Mohammad Kermanshahi Hospital, Kermanshah city, Iran. Age and sex were identified for every patient. Aberrant Markers of flow cytometry were checked for a number of patients. Positive staining of the markers was shown based on three cuts-off that >15%, >20% or >30%. Out of 132 leukemia samples, 67 cases (50.8%) had CLL (all BCLL), 38 cases (28.8%) had ALL (11 T-ALL and 27 B-ALL) and 27 cases (20.4%) had AML-non M3. The mean age at diagnosis for CLL patients was 65.3 years, AML 39.2 years and ALL 13.6 years. CD2, CD3 and CD7 were checked in some of B-CLL and AML-non M3 patients and CD3 in B-ALL patients as aberrant markers and showed positivity, however, further studies are needed for evaluation of prognosis, therapy, response and survival in patients with these aberrant markers.